Cargando…
Blood‐based biopsies—clinical utility beyond circulating tumor cells
Circulating tumor cells (CTCs), epithelial–mesenchymal transition (EMT) cells, as well as a number of circulating cancer stromal cells (CStCs) are known to shed into the blood of cancer patients. Individually, and together, these cells provide biological and clinical information about the cancers. F...
Autores principales: | Tang, Cha‐Mei, Zhu, Peixuan, Li, Shuhong, Makarova, Olga V., Amstutz, Platte T., Adams, Daniel L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6370292/ https://www.ncbi.nlm.nih.gov/pubmed/30369050 http://dx.doi.org/10.1002/cyto.a.23573 |
Ejemplares similares
-
Centrifugation affects the purity of liquid biopsy‐based tumor biomarkers
por: Rikkert, Linda G., et al.
Publicado: (2018) -
The RareCyte® platform for next‐generation analysis of circulating tumor cells
por: Kaldjian, Eric P., et al.
Publicado: (2018) -
How to Agree on a CTC: Evaluating the Consensus in Circulating Tumor Cell Scoring
por: Zeune, Leonie L., et al.
Publicado: (2018) -
The Parsortix™ Cell Separation System—A versatile liquid biopsy platform
por: Miller, M. Craig, et al.
Publicado: (2018) -
Automated rare single cell picking with the ALS cellcelector™
por: Nelep, Constantin, et al.
Publicado: (2018)